rabeprazole has been researched along with Liver Cirrhosis in 3 studies
Rabeprazole: A 4-(3-methoxypropoxy)-3-methylpyridinyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.
Liver Cirrhosis: Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To investigate whether or not CYP2C19 genotype status is associated with cure rate for Helicobacter pylori infection in patients with cirrhosis and peptic ulcer, achieved with 2 weeks of triple therapy with rabeprazole, amoxicillin and clarithromycin." | 3.76 | Correlation of CYP2C19 genetic polymorphisms with helicobacter pylori eradication in patients with cirrhosis and peptic ulcer. ( Lay, CS; Lin, CJ; Lin, JR, 2010) |
| "Rabeprazole was well tolerated by both groups." | 2.69 | Rabeprazole: pharmacokinetics in patients with stable, compensated cirrhosis. ( Grimes, I; Hoyumpa, AM; Humphries, TJ; Trevino-Alanis, H, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tsai, CF | 1 |
| Chen, MH | 1 |
| Wang, YP | 1 |
| Chu, CJ | 1 |
| Huang, YH | 1 |
| Lin, HC | 1 |
| Hou, MC | 1 |
| Lee, FY | 1 |
| Su, TP | 1 |
| Lu, CL | 1 |
| Lay, CS | 1 |
| Lin, CJ | 1 |
| Lin, JR | 1 |
| Hoyumpa, AM | 1 |
| Trevino-Alanis, H | 1 |
| Grimes, I | 1 |
| Humphries, TJ | 1 |
1 trial available for rabeprazole and Liver Cirrhosis
| Article | Year |
|---|---|
Rabeprazole: pharmacokinetics in patients with stable, compensated cirrhosis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Benzimidazoles; Chronic Disease; Enzyme Inhibitors; | 1999 |
2 other studies available for rabeprazole and Liver Cirrhosis
| Article | Year |
|---|---|
Proton Pump Inhibitors Increase Risk for Hepatic Encephalopathy in Patients With Cirrhosis in A Population Study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administrative Claims, Healthcare; Adult; Aged; Case-Contro | 2017 |
Correlation of CYP2C19 genetic polymorphisms with helicobacter pylori eradication in patients with cirrhosis and peptic ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Clarithr | 2010 |